DSIP was named for deep sleep. Decades later, the link is still unproven
Delta sleep-inducing peptide was found in 1977. Its gene, its receptor and a reliable sleep effect have never been pinned down.
At a glance
- Discovered
- 1977, in blood from the brains of rabbits, by a group in Basel
- Gene or receptor
- Never isolated
- Sleep effect
- Some lab-made relatives, but not DSIP itself, promoted deep sleep in rabbits and rats
- 2006 review
- Called the sleep-factor idea “extremely poorly documented and still weak”
- Regulation
- Discussed by FDA advisers in July 2026 as a possible compounding ingredient
The research, explained
DSIP is a nine-amino-acid peptide. A research group in Basel isolated it in 1977 from blood draining the brains of rabbits and proposed it as a natural sleep-promoting factor. The name, delta sleep-inducing peptide, refers to deep slow-wave sleep.
The name stuck, but the evidence didn’t follow. A 2006 review in the Journal of Neurochemistry noted that no gene, precursor protein or receptor for DSIP had been isolated, and called the idea that DSIP is a sleep factor “extremely poorly documented and still weak”.
One detail stands out. In the reviewers’ own early studies, certain lab-made DSIP analogues promoted deep sleep in rabbits and rats, but DSIP itself did not. They suggested that an undiscovered DSIP-like peptide might explain the activity researchers had seen.
In July 2026, FDA advisers discussed DSIP (also called emideltide) as a possible compounding ingredient for opioid withdrawal, insomnia and narcolepsy. That discussion is not an approval (read our report).
DSIP research material, where listed, is in the research shop for laboratory use.
What does this mean?
DSIP is an unsolved puzzle from sleep research rather than a proven sleep aid.
What don’t we know yet?
What DSIP does in the body, whether it affects sleep in people, and how safe it is remain open questions.
Watch and learn
Videos discussing the compounds in this article, plus background on the biology or the research methods. Each card explains its connection; recordings may predate the findings described here.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 24, 2026
Full meeting covering DSIP (emideltide), Semax and Epitalon. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Official regulatory recording
The original July 24, 2026 FDA discussion of DSIP, Semax and Epitalon; it documents an advisory review.
khanacademymedicine
Types of neurotransmitters
The roles of signalling molecules such as GABA, glutamate and peptide neurotransmitters.
Khan Academy · nervous-system physiology
Related biology
Background on neurotransmitter biology for understanding DSIP. It does not demonstrate benefits of this compound or formulation.
National Institute of Mental Health
What is clinical research?
Why studies in people are needed and what clinical research is designed to establish.
NIMH · US National Institutes of Health
Research skills
Helps you judge the study design or uncertainty in DSIP research; it is not a trial of the compound.
Sources and references
- Delta sleep-inducing peptide (DSIP): a still unresolved riddleKovalzon & Strekalova · Journal of Neurochemistry · 2006
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
